
|Articles|July 31, 2007
Survey: What Will You Do About Rosiglitazone (Avandia)?
Take this MedPage Today survey.
Advertisement
On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Real-World Study Shows Intranasal Epinephrine Effectively Treats Most Allergic Reactions with a Single Dose
2
Understanding Alzheimer’s Agitation: Survey Points to Missed Diagnoses and Caregiver Burden
3
Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes
4
Donna Plecha, MD: The Real Barriers to Optimal Breast Cancer Screening in Women with Dense Breasts
5

































































































































































































































































































